Autres langues Modus Therapeutics Holding AB

Actions

MODTX

SE0015987904

Recherche biotechnologique et médicale

Temps Différé Nasdaq Stockholm 09:28:09 08/10/2026			Varia. 5j.	Varia. 1 janv.
0,3990 ^SEK	+2,31%		+5,00%	+31,25%

04/09	Modus Therapeutics, société du portefeuille de KD Ventures, réalise une augmentation de capital réservée	FW
26/08	Modus Therapeutics Holding AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

29/09	Modus announces outcome of the first exercise period for warrants of series TO 2030; receives approximately SEK 134 thousand
11/09	Modus Therapeutics : The first exercise period for Modus Therapeutics' warrants of series TO 2030 commences on 14 September 2026
11/09	The first exercise period for Modus Therapeutics’ warrants of series TO 2030 commences on 14 September 2026
04/09	KDventures portfolio company Modus Therapeutics carries out a directed issue of MSEK 7.6
03/09	Modus Therapeutics carries out a directed issue of SEK 7.6 million
26/08	Modus Therapeutics Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
26/08	Modus Therapeutics publishes interim report for Q2 2026
18/06	Modus Therapeutics: SEVUSMART manuscript made available online ahead of peer review in Nature Communications
16/06	Modus Therapeutics Holding AB Reports on Preclinical Data on Sevuparin in CKD with Anemia Presented at EHA2026
16/06	Modus Therapeutics reports on preclinical data on sevuparin in CKD with anemia presented at EHA2026
28/05	Annual General Meeting in Modus Therapeutics Holding AB (publ)
28/05	Modus Therapeutics Holding AB Approves Board Elections
26/05	Modus Therapeutics Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2026
26/05	Modus Therapeutics publishes interim report for Q1 2026
21/05	Modus Therapeutics to present sevuparin data at the European Iron Club Meeting 2026 in Dublin
13/05	Modus Therapeutics to present preclinical data on sevuparin in CKD with anemia at EHA2026 in Stockholm
13/05	Modus Therapeutics Holding AB Presents Preclinical Data On Sevuparin In Chronic Kidney Disease Anaemia At EHA2026
28/04	Modus Therapeutics to Raise SEK10 Million From Warrant Exercise
28/04	Modus Therapeutics To Receive SEK 9.5 Mln From Warrants
27/04	Modus announces outcome of exercise of warrants of series TO 2026 and receives approximately SEK 9.5 million
27/04	Notice to Annual General Meeting in Modus Therapeutics Holding
15/04	Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2025
15/04	Modus Therapeutics Holding AB Auditor Raises 'Going Concern' Doubt
14/04	KDventures AB subscribes for all of its warrants of series 2025/2026 in Modus Therapeutics
14/04	KDventures exercises its share of the portfolio company Modus Therapeutics’ warrant program TO2